Telemedicine and COVID-19 pandemic: The perfect storm to mark a change in diabetes care. Results from a world-wide cross-sectional web-based survey.
COVID-19
pediatrics
telehealth
telemedicine
type 1 diabetes
virtual
Journal
Pediatric diabetes
ISSN: 1399-5448
Titre abrégé: Pediatr Diabetes
Pays: Denmark
ID NLM: 100939345
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
08
09
2021
received:
29
07
2021
accepted:
22
09
2021
pubmed:
7
11
2021
medline:
15
12
2021
entrez:
6
11
2021
Statut:
ppublish
Résumé
Telemedicine for routine care of people with diabetes (PwD) during the COVID-19 pandemic rapidly increased in many countries, helping to address the several barriers usually seen. This study aimed to describe healthcare professionals' (HCPs) experience on telemedicine use in diabetes care and investigate the changes and challenges associated with its implementation. A cross-sectional electronic survey was distributed through the global network of JENIOUS members of ISPAD. Respondents' professional and practice profiles, clinic sizes, their country of practice, and data regarding local telemedicine practices during COVID-19 pandemic were investigated. Answers from 209 HCPs from 33 countries were analyzed. During the pandemic, the proportion of PwD receiving telemedicine visits increased from <10% (65.1% of responders) to >50% (66.5%). There was an increase in specific privacy requirements for remote visits (37.3% to 75.6%), data protection policies (42.6% to 74.2%) and reimbursement for remote care (from 41.1% to 76.6%). Overall, 83.3% HCPs reported to be satisfied with the use of telemedicine. Some concerns (17.5%) about the complexity and heterogeneity of the digital platforms to be managed in everyday practice remain, feeding the need for unifying and making interoperable the tools for remote care. Also, 45.5% of professionals reported to feel stressed by the need for extra-time for telemedicine consultations. Telemedicine was rapidly and broadly adopted during the pandemic globally. Some issues related to its use were promptly addressed by local institutions. Challenges with the use of different platforms and for the need of extra-time still remain to be solved.
Sections du résumé
BACKGROUND
Telemedicine for routine care of people with diabetes (PwD) during the COVID-19 pandemic rapidly increased in many countries, helping to address the several barriers usually seen.
OBJECTIVE
This study aimed to describe healthcare professionals' (HCPs) experience on telemedicine use in diabetes care and investigate the changes and challenges associated with its implementation.
METHODS
A cross-sectional electronic survey was distributed through the global network of JENIOUS members of ISPAD. Respondents' professional and practice profiles, clinic sizes, their country of practice, and data regarding local telemedicine practices during COVID-19 pandemic were investigated.
RESULTS
Answers from 209 HCPs from 33 countries were analyzed. During the pandemic, the proportion of PwD receiving telemedicine visits increased from <10% (65.1% of responders) to >50% (66.5%). There was an increase in specific privacy requirements for remote visits (37.3% to 75.6%), data protection policies (42.6% to 74.2%) and reimbursement for remote care (from 41.1% to 76.6%). Overall, 83.3% HCPs reported to be satisfied with the use of telemedicine. Some concerns (17.5%) about the complexity and heterogeneity of the digital platforms to be managed in everyday practice remain, feeding the need for unifying and making interoperable the tools for remote care. Also, 45.5% of professionals reported to feel stressed by the need for extra-time for telemedicine consultations.
CONCLUSIONS
Telemedicine was rapidly and broadly adopted during the pandemic globally. Some issues related to its use were promptly addressed by local institutions. Challenges with the use of different platforms and for the need of extra-time still remain to be solved.
Identifiants
pubmed: 34741569
doi: 10.1111/pedi.13272
pmc: PMC8661953
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1115-1119Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Diabetes Technol Ther. 2021 Sep;23(9):642-651
pubmed: 33851873
Telemed J E Health. 2019 Jul;25(7):569-583
pubmed: 30124394
Diabetes Technol Ther. 2020 Dec;22(12):920-928
pubmed: 32191141
J Am Board Fam Med. 2021 Feb;34(Suppl):S61-S70
pubmed: 33622820
Pediatr Diabetes. 2021 May;22(3):463-468
pubmed: 33470020
JMIR Mhealth Uhealth. 2021 Apr 5;9(4):e24374
pubmed: 33571104
Healthcare (Basel). 2021 Jun 28;9(7):
pubmed: 34203306
Exp Clin Endocrinol Diabetes. 2021 Nov;129(11):831-836
pubmed: 32380561
Pediatr Diabetes. 2021 Dec;22(8):1115-1119
pubmed: 34741569
J Clin Transl Endocrinol Case Rep. 2021 Mar;19:100078
pubmed: 33527071
Public Health. 2020 Aug;185:1-2
pubmed: 32502747
Diabetes Metab Syndr. 2020 Sep - Oct;14(5):797-799
pubmed: 32534432
Diabetes Technol Ther. 2020 Jun;22(6):431-439
pubmed: 32302499
Diabetes Technol Ther. 2020 Aug;22(8):623-638
pubmed: 32027176
Diabetes Technol Ther. 2021 Feb;23(2):146-154
pubmed: 32905711
Acta Diabetol. 2018 Feb;55(2):185-192
pubmed: 29209814
Eur J Endocrinol. 2020 Aug;183(2):G67-G77
pubmed: 32508313
Endocrinol Diabetes Metab. 2020 Aug 29;4(1):e00180
pubmed: 33532617